Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mainz Biomed NV MYNZ

Healthcare Biotechnology
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of... see more

Recent & Breaking News (NDAQ:MYNZ)

Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts

GlobeNewswire September 28, 2022

Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board

GlobeNewswire September 20, 2022

Mainz Biomed Reports First Half 2022 Financial Results

GlobeNewswire September 7, 2022

Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire September 1, 2022

Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board

GlobeNewswire August 23, 2022

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

GlobeNewswire August 16, 2022

Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development

GlobeNewswire August 3, 2022

Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

GlobeNewswire July 19, 2022

Mainz Biomed Today to Provide Corporate Update for First Half of 2022

GlobeNewswire July 12, 2022

Mainz Biomed Provides Corporate Update for First Half of 2022

GlobeNewswire July 5, 2022

Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

GlobeNewswire June 28, 2022

Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission

GlobeNewswire June 14, 2022

Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

GlobeNewswire June 1, 2022

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

GlobeNewswire May 19, 2022

Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference

GlobeNewswire May 17, 2022

Mainz Biomed to Host Key Opinion Leader Event at DDW 2022

GlobeNewswire May 9, 2022

Mainz Biomed Provides Product Development Update on PancAlert

GlobeNewswire May 5, 2022

Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer

GlobeNewswire April 26, 2022

Mainz Biomed Announces First Quarter 2022 Results

GlobeNewswire April 12, 2022

Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert's Pivotal Clinical Trial

GlobeNewswire March 31, 2022